EarningsQ2 2026 Earnings Report
CH:SR3 Q2 2026 EPS Results
Actual EPSCHF0.13
Consensus EPSCHF0.18
Beat/MissMissed by -CHF0.05
One Year Ago EPS-CHF0.28
CH:SR3 Q2 2026 Revenue Results
Actual RevenueCHF77.84M
Expected RevenueCHF75.39M
Beat/MissBeat by +CHF2.44M
YoY Revenue Growth+111.04%
Earnings Announcement Details
QuarterQ2 2026
Date08/12/2026
TimeAfter Close
Conference CallWednesday, August 12, 2026
CH:SR3 Upcoming Earnings
Staar Surgical's next earnings date is estimated for November 4, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CH:SR3 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted a strong operational and financial recovery: record first-half revenue, significant YoY top-line growth (Q2 net sales +111%), return to profitability (net income $8.1M; adjusted EBITDA $20M), improved cash balance and strategic progress on product launches (EVO Plus) and ERP deployment. Key risks remain—supply constraints (EVO Plus demand outstripping capacity), tariff-related margin pressure until Swiss manufacturing is fully ramped, regional seasonality and market variability (China seasonality, EMEA/Middle East impacts), and near-term ERP and transition costs. On balance the positive financial turnaround, market share gains in China, and clear roadmap for innovation outweigh the operational headwinds.Company Guidance
Record First-Half Revenue and Strong Q2 Sales
Net sales of $93.5M in Q2 2026, up 111% year-over-year versus $44.3M; company reported the strongest first-half revenue performance in STAAR history. Management called out back-to-back record quarters in the U.S.
China Recovery and EVO Plus Launch
China net sales grew 100%+ year-over-year and increased 10% sequentially to $52.3M. EVO Plus adoption was a notable driver (approximately one-third of China units at quarter end) and management reported market share gains attributable to EVO Plus.
Regional Growth Outside China
APAC net sales up 189% YoY (excluding China APAC up 7% YoY). Americas grew 12% YoY with the U.S. delivering a second consecutive ~ $6M quarter. EMEA excluding the Middle East grew 12% YoY.
Profitability Turnaround
Net income of $8.1M (EPS $0.16) vs. a net loss of $16.8M (EPS -$0.34) in the prior year quarter. Adjusted EBITDA of $20M (vs. adjusted EBITDA loss of $14.8M prior year).
Strong Gross Margin and Cash Position
Gross margin improved to 74.5% from 74.0% year-over-year (0.5 ppt improvement). Cash, cash equivalents and investments rose to $181.5M from $163.9M at Q1-end (increase of ~$17.6M, ~10.7%), and the company has no debt and expects to finish 2026 with well over $200M in cash.
ERP Implementation Completed and Operationalizing
ERP system went live in the quarter; management reported continued sales and customer support during the transition and plan to optimize the system in Q3 while building toward AI-enabled capabilities.
Innovation Roadmap and Pipeline Progress
Management emphasized accelerating innovation beyond a single product: R&D preparing for first-in-human studies on next-generation product(s), search underway for a chief technology officer, and continued emphasis on Collamer-based lens platform.
Unit and Market Traction in Key Markets
Japan unit volume rose 14% (reported sales +2% due to currency headwinds); Taiwan showing strong sequential growth after recent launch; company has sold over 4 million lenses across 85 countries with 32 years of Collamer clinical history.
CH:SR3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed